Evolus Inc
NASDAQ:EOLS

Watchlist Manager
Evolus Inc Logo
Evolus Inc
NASDAQ:EOLS
Watchlist
Price: 12.6 USD -3.37% Market Closed
Market Cap: 797.8m USD
Have any thoughts about
Evolus Inc?
Write Note

Evolus Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Evolus Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Evolus Inc
NASDAQ:EOLS
Depreciation & Amortization
-$5.3m
CAGR 3-Years
12%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Depreciation & Amortization
-$9.5B
CAGR 3-Years
2%
CAGR 5-Years
-170%
CAGR 10-Years
-55%
Pfizer Inc
NYSE:PFE
Depreciation & Amortization
-$5.2B
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Evolus Inc
Glance View

Market Cap
797m USD
Industry
Pharmaceuticals

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 167 full-time employees. The company went IPO on 2018-02-08. The Company’s first commercial product is Jeuveau, which is an approximately 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company offers customers and consumers a compelling value proposition with Jeuveau. BOTOX (onabotulinumtoxinA) is also an approximately 900 kDa botulinum toxin type A complex approved in the United States.

EOLS Intrinsic Value
17.71 USD
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Evolus Inc's Depreciation & Amortization?
Depreciation & Amortization
-5.3m USD

Based on the financial report for Sep 30, 2024, Evolus Inc's Depreciation & Amortization amounts to -5.3m USD.

What is Evolus Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-15%

Over the last year, the Depreciation & Amortization growth was -11%. The average annual Depreciation & Amortization growth rates for Evolus Inc have been 12% over the past three years , -15% over the past five years .

Back to Top